XML 36 R22.htm IDEA: XBRL DOCUMENT v3.3.1.900
ASSETS (Tables)
12 Months Ended
Dec. 31, 2015
Assets Tables  
Schedule of Inventory
    December 31,  
    2015     2014  
Raw materials and supplies   $ 77,649     $ 191,186  
Work in process      90,540       -  
Finished goods     86,254       74,773  
Total   $ 254,443     $ 265,959  
Schedule of Property and Equipment
    December 31,    
    2015     2014  
Computer equipment   $ 5,254     $ 5,254    
Office furniture and fixtures     33,376       33,376    
Production equipment     276,479       266,939    
Software     338,976       338,976    
    Total cost     654,085       644,545    
Less accumulated depreciation     618,984       590,034    
    Property and equipment, net   $ 35,101     $ 54,511    
Schedule of Intangible Assets

December 31, 2015

 

    Amount    

Accumulated

Amortization

    Net Amount    

Useful Lives

(years)

                         
Patent & Trademarks   $ 417,597     $  57,593     $  360,004     7 - 15
Customer Contracts     611,119        127,316        483,803     10
Sensum+® License (from CRI)     234,545        60,554        173,991     10
Vesele® trademark     25,287        3,886        21,401     8
Novalere Mfg. Contract     4,681,000        419,340        4,261,660     10
 Total   $ 5,969,548     $  (668,689 )   $  5,300,859      

 

December 31, 2014

 

     Amount     Accumulated  Amortization      Net Amount    

Useful Lives

(years)

                             
Patent & Trademarks   $ 264,321     $ (23,671 )   $ 240,650     7 - 14
Customer Contracts     611,119       (62,262 )     548,857     10
Sensum+® license (from CRI)     272,545       (31,250 )     241,295     10
Vesele® trademark     25,287       (717 )     24,570     8
 Total   $ 1,173,272     $ (117,900 )   $ 1,055,372      

 

Schedule of Goodwill
    December 31, 2015    
           
Beginning balance December 31, 2013   $ 421,372    
Purchase price adjustment for acquisition of Semprae Laboratories, Inc. in 2013     7,853    
Ending Balance December 31, 2014     429,225    
Acquisition of Novalere (see Note 3)     120,143  
Release of valuation allowance in connection with acquisition of Novalere (see Note 10)     759,428  
Impairment of valuation allowance in connection with acquisition of Novalere (see Note 10)     (759,428  )
Ending Balance December 31, 2015   $ 549,368